A 52-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2010
This article has no abstract
Epistemonikos ID: c8ab27422e0c7e36c604cffea82808b97f5d58af
First added on: Apr 16, 2025